What's happening
Live detector signal
Generated 13:14 ET
MTNB — Matinas BioPharma Holdings, Inc is down 34.0%, at 1.56, on $179.4K traded. Score 70. Primary driver: $179K traded. Supply intelligence: mixed supply · 46.
Get alerts on $MTNB
Halts, resumptions, new filings, and updated reports — in your inbox within minutes of the event.
Free · one email per event, no digests or spam · unsubscribe anytime · joins real followers
Free float
—, refreshing
2026-09-22
Shares out
979.5K
latest detail
Market cap
$2.3M
at ref price
Short interest
0.5%
2026-09-30
Float rotation
0.01×
latest snapshot
20d dollar vol
$360.3K
baseline
Gap quality
mixed supply · 46
live supply-pressure model
Supply factor
negative gap pressure
detector reason
Supply factor
low float
detector reason
Supply factor
nano-cap supply profile
detector reason
Supply factor
recent reverse split dilution risk
detector reason
This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.
2026-10-19 13:10 ETSignalMatinas BioPharma Holdings, Inc is down 34.0%, at 1.56, on $179.4K traded. Score 70. Primary driver: $179K traded. Supply intelligence: mixed supply · 46.
2026-09-28Split1-for-15 reverse split logged
2026-09-288-KItem 3.03 — Material modification to rights of security holders; Item 5.03 — Amendments to charter or bylaws +1 more SEC
2026-09-048-KItem 3.01 — Notice of delisting or failure to satisfy listing rule; Item 8.01 — Other events +1 more SEC
2026-07-138-KItem 1.01 — Entry into a material definitive agreement; Item 3.02 — Unregistered sales of equity securities +1 more SEC
2026-06-26 17:15 ETGeneralMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance News
2024-06-24 08:30 ETFDA / ClinicalMatinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program News
2024-06-13 07:00 ETGeneralMatinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin News
2024-05-16 07:00 ETFDA / ClinicalNew In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 News
Latest detector signalscore 70